Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study to Assess Gemtuzumab, in Combination With Standard Chemotherapy, on MRD Levels, in Adult, 18-60 Years, With Previously Untreated de Novo Fav-interm Risk AML

NCT04168502 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

NCT NCT04168502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04168502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study to Assess Gemtuzumab, in Combination With Standard Chemotherapy, on MRD Levels, in Adult, 18-60 Years, With Previously Untreated de Novo Fav-interm Risk AML
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Phase 3
Overall status
Recruiting
Start date
September 24, 2020
Completion date
April 30, 2027
Enrollment
414 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia